Medicare told to reassess premium hike for Alzheimer’s drug

WASHINGTON (AP) — U.S. health secretary Xavier Becerra is ordering Medicare to reassess a big premium increase facing millions of enrollees this year. The increase was largely attributed to a pricey new Alzheimer’s drug with questionable benefits. Becerra’s directive on Monday comes days after drugmaker Biogen slashed the price of its $56,000-a-year medication, Aduhelm, to…